Skip to main content
SpringerLink
Log in

Pharmacology of antimigraine drugs

  • Review Of Migraine And Its Therapy
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Summary

The drugs used in migraine therapy can be divided into two groups: agents that abort an established migraine attack and agents used prophylactically to reduce the number of migraine attacks. Both groups have drugs that are specific for migrainous headaches and that are non-specific, and are used to treat the accompanying headache (analgesics), vomiting (anti-emetics), anxiety (sedatives and anxiolytics), or depression (antidepressants). The main drugs with specific action on migraine include ergot alkaloids (ergotamine, dihydroergotamine), agonists (sumatriptan) or partial agonists (methysergide) at a specific subtype of 5-HT1-like receptors, β-adrenoceptor antagonists (propranolol, metoprolol), calcium antagonists (flunarizine) and anti-inflammatory agents (indomethacin). The pharmacological basis of therapeutic action of several of these drugs is not well understood. In the case of the ergot alkaloids and 5-HT1-like receptor agonists, however, it is likely that the antimigraine effect is related to the potent and rather selective constriction of the large arteries and arteriovenous anastomoses in the scalp and dural regions. In addition, these drugs inhibit plasma extravasation into the dura in response to trigeminal ganglion stimulation, but it is possible that this effect is related to the selective vasoconstriction in the extracerebral vascular bed. The selectivity of the pharmacological effects of these antimigraine drugs (constriction of the extracerebral arteries and arteriovenous anastomoses, poor penetration into the central nervous system and the absence of an antinociceptive effect even after intrathecal administration) strongly suggests that excessive dilatation in the extracerebral cranial vasculature, probably initiated by a neuronal event, is an integral part of the pathophysiology of migraine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aellig WH (1983) Influence of pizotifen and ergotamine on the vasoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man. Eur J Clin Pharmacol 25:759–762

    Google Scholar 

  2. Albers GW, Simon LT, Hamik A, Peroutka SJ (1989) Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 29:215–218

    Google Scholar 

  3. Amano T, Meyer JS (1982) Cerebrovascular changes in patients with headache during antiserotonergic treatment. Headache 22:249–255

    Google Scholar 

  4. Ansell E, Fazzone T, Festenstein R, Johnson ES, Thavalpalan M, Wilkinson M, Wozniak I (1988) Nimodipine in migraine prophylaxis. Cephalalgia 8:269–272

    Google Scholar 

  5. Bateman DN, Kahn C, Davies DS (1980) The pharmacokinetics of metoclopramide in man. J Clin Pharmacol 9:371–377

    Google Scholar 

  6. Behan PO (1980) Prophylactic migraine therapy. J Drug Res 5 (suppl):53–57

    Google Scholar 

  7. Blau JN (ed) (1987) Migraine, clinical, therapeutic, conceptual and research aspects. Chapman and Hall, London

    Google Scholar 

  8. Bom AH, Heiligers JPC, Saxena PR, Verdouw PD (1989) Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors. Br J Pharmacol 97:383–390

    Google Scholar 

  9. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576

    Google Scholar 

  10. Brand J, Hadoke M, Perrin VL (1987) Placebo-controlled study of a selective 5-HT1-like agonist, AH25086B, in relief of acute migraine. Cephalalgia 7 (suppl 6):402–403

    Google Scholar 

  11. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone. A review on its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24:360–400

    Google Scholar 

  12. Buzzi MG, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206

    Google Scholar 

  13. Dallas FAA, Dixon CM, McCulloch RJ, Saynor DA (1989) The kinetics of 14C-GR43175 in rat and dog. Cephalalgia 9 (suppl 9):53–56

    Google Scholar 

  14. Den Boer MO, Villalòn CM, Heiligers JPC, Saxena PR, Humphrey PPA (1990) The craniovascular effects of sumatriptan. Br J Pharmacol 99:37P

  15. Den Boer MO, Villalòn CM, Heiligers JPC, Humphrey PPA, Saxena PR (1991) Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol (in press)

  16. Diamond S, Kudrow L, Stevens J, Shapiro DB (1982) Long-term study of propranolol in the treatment of migraine. Headache 22:268–271

    Google Scholar 

  17. Doenicke A, Siegel E, Hadoke A, Perrin VL (1987) Initial clinical study of AH25086B, in relief of acute migraine. Cephalalgia 7 (suppl 6):402–403

    Google Scholar 

  18. Feniuk W, Humphrey PPA, Perren MJ (1989) The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol 96:83–90

    Google Scholar 

  19. Forssman B, Lindblad CJ, Zbornikova V (1983) Atenolol for migraine prophylaxis. Headache 23:188–190

    Google Scholar 

  20. Gelmers HJ (1985) Calcium-channel blockers in the treatment of migraine. Am J Cardiol 55:139B-143B

    Google Scholar 

  21. Glover V, Sandler M (1989) Can the vascular and neurogenic theories of migraine finally be reconciled? Trends Pharmacol Sci 10:1–3

    Google Scholar 

  22. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC (1983) Metoclopramide. An up-dated view of its pharmacological properties and clinical use. Drugs 25:451–494

    Google Scholar 

  23. Headache Classification Committee, International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 (suppl 7):10–73

    Google Scholar 

  24. Hedman C, Andersen AR, Andersson PG, Gilhus NG, Kangasniemi P, Olsson JE, Strandman E, Nestvold K, Olesen J (1988) Symptoms of classic migraine attacks: modifications brought about by metoprolol. Cephalalgia 8:279–284

    Google Scholar 

  25. Heyck H (1969) Pathogenesis of migraine. Res Clin Stud Headache 2:1–28

    Google Scholar 

  26. Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates IH, Butina D (1988) GR43175, a selective agonist for the 5-HT1-like receptor in the dog saphenous vein. Br J Pharmacol 94:1123–1132

    Google Scholar 

  27. Humphrey PPA, Perren MJ, Feniuk W, Connor HE, Oxford AW (1989) The pharmacology of a novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 9 (suppl 9):23–33

    Google Scholar 

  28. Humphrey PPA, Apperly E, Feniuk W, Perren MJ (1990) A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine, prospective therapeutic applications. Kluwer, Dordrecht, pp 417–428

    Google Scholar 

  29. Ibraheem JJ, Paalzow L, Tfelt-Hansen P (1983) Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 16:695–699

    Google Scholar 

  30. Kerber CW, Newton TH (1973) The macro- and microvasculature of the dura mater. Neuroradiology 6:175–179

    Google Scholar 

  31. Louis P, Spierings EL (1982) Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalalgia 2:197–203

    Google Scholar 

  32. Lucking CH, Oestreich W, Schmidt R, Soyka D (1988) Flunarizine vs propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia 8 (suppl 8):21–26

    Google Scholar 

  33. McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ (1989) Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 39:284–286

    Google Scholar 

  34. Müller-Schweinitzer E (1986) Serotonergic receptors in brain vessels. In: Owman C, Hardebo JE (eds) Neural regulation of brain circulation. Elsevier, Amsterdam, pp 219–234

    Google Scholar 

  35. Müller-Schweinitzer E, Weidmann H (1978) Basic pharmacological properties. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Handbook of experimental pharmacology. Springer, Berlin pp 87–232

    Google Scholar 

  36. Nielsen TH, Tfelt-Hansen P (1989) Lack of effect of GR43175 on peripheral arteries in man. Cephalalgia 9 (suppl 9):93–95

    Google Scholar 

  37. Parsons AA, Whalley ET (1989) Characterization of the 5-hydroxytryptamine receptor which mediates contraction of the human isolated basilar artery. Cephalalgia 9 (suppl 9):47–51

    Google Scholar 

  38. Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16:687–699

    Google Scholar 

  39. Perren MJ, Feniuk W, Humphrey PPA (1989) The selective closure of feline arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 9 (suppl 9):41–46

    Google Scholar 

  40. Perrin VL, Färkkilä M, Goasguen J, Doenicke A, Brand J, Tfelt-Hansen P (1989) Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (suppl 9):63–72

    Google Scholar 

  41. Puzich R, Girke W, Heidrich H, Rischke M (1983) Dopplersonographische Untersuchungen der extrakraniellen Hirngefäse bei Migräne-Patienten nach Gabe von Ergotamintartrat. Dtsch Med Wochenschr 108:457–461

    Google Scholar 

  42. Rall TW, Schleifer LS (1985) Oxytocin, prostaglandins, ergot alkaloids and other drugs; toxicolytic agents. In: Goodman-Gilman A, Goodman LS, Rall TW, Murat F (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 926–945

    Google Scholar 

  43. Rowbotham GF, Little E (1965) New concepts on the aetiology and vascularization of meningiomata: the mechanism of migraine; the chemical process of cerebrospinal fluid; and the formation of collections of blood or fluid in the subdural space. Br J Surg 52:21–24

    Google Scholar 

  44. Ryan RE, Jr, Ryan RE (1975) Clonidine — its use in migraine therapy. Headache 14:190–192

    Google Scholar 

  45. Saito K, Markowitz S, Moskowitz MA (1988) Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 24:732–737

    Google Scholar 

  46. Saxena PR (1972) The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action. Headache 12:44–54

    Google Scholar 

  47. Saxena PR (1974) Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Eur J Pharmacol 27:99–105

    Google Scholar 

  48. Saxena PR (1987) Arteriovenous anastomoses and veins in migraine research. In: Blau JN (ed) Migraine, clinical, therapeutic, conceptual and research aspects. Chapman and Hall, London, pp 581–596

    Google Scholar 

  49. Saxena PR (1990) Is there still a case for the shunt hypothesis in migraine? In: Sandler M, Collins G (eds) Migraine, a spectrum of ideas. Oxford Medical Publications, Oxford, pp 191–197

    Google Scholar 

  50. Saxena PR (1990) 5-HT receptors and migraine. In: Sandler M, Collins G (eds) Migraine, a spectrum of ideas. Oxford Medical Publications, Oxford, pp 162–190

    Google Scholar 

  51. Saxena PR, de Vlaam-Schluter GM (1974) Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine. Studies in an experimental model for migraine. Headache 13:142–163

    Google Scholar 

  52. Saxena PR, Ferrari MD (1989) 5-HT1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 10:200–204

    Google Scholar 

  53. Saxena PR, Verdouw PD (1982) Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous blood flow. J Physiol 332:501–520

    Google Scholar 

  54. Saxena PR, Verdouw PD (1984) Effects of methysergide and 5-hydroxytryptamine (5-HT) on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol 82:817–826

    Google Scholar 

  55. Saxena PR, Verdouw PD (1985) Tissue blood flow and arteriovenous shunting in pigs measured with microspheres of four different sizes. Pflügers Arch 403:128–135

    Google Scholar 

  56. Saxena PR, van Houwelingen P, Bonta IL (1971) The effect of mianserin hydrochloride on the vascular responses to 5-hydroxytryptamine and related substances. Eur J Pharmacol 13:295–305

    Google Scholar 

  57. Saxena PR, Duncker DJ, Bom AH, Heiligers JPC, Verdouw PD (1986) Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: evidence for the presence of “5-hydroxytryptamine1-like” receptors. Naunyn Schmiedebergs Arch Pharmacol 333:198–204

    Google Scholar 

  58. Saxena PR, Bom AH, Verdouw PD (1989) Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Cephalalgia 9 (suppl 9):15–22

    Google Scholar 

  59. Schamhardt HC, Verdouw PD, Van der Hoek TM, Saxena PR (1979) Regional myocardial perfusion and wall thickness and arteriovenous shunting after ergotamine administration to pigs with a fixed coronary stenosis. J Cardiovasc Pharmacol 1:673–686

    Google Scholar 

  60. Shanks RG (1985) Mechanism of action of beta-adrenoceptor antagonists in migraine. In: Carroll JD, Pfaffenrath V, Sjaastad O (eds) Migraine and beta-blockade. Hässle, Mölndal, pp 45–53

    Google Scholar 

  61. Sjaastad O, Dale I (1976) A new (?) clinical headache entity; “chronic paroxysmal hemicrania”. Acta Neurol Scand 54:140–159

    Google Scholar 

  62. Sjaastad O, Spierings ELH (1984) Hemicrania continua: another headache absolutely responsive to indomethacin. Cephalalgia 4:65–70

    Google Scholar 

  63. Solomon GD (1989) Verapamil in migraine prophylaxis — a five year review. Headache 29:425–427

    Google Scholar 

  64. Speight TM, Avery TM (1972) Pizotifen (BC 105): a review on its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 3:159–203

    Google Scholar 

  65. Stellar S, Ahrers SP, Meibohm AR, Reines SA (1984) Migraine prevention with timolol: a double crossover study. J Am Med Assoc 252:2576–2580

    Google Scholar 

  66. Stensrud P, Sjaastad O (1980) Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 20:204–207

    Google Scholar 

  67. Tfelt-Hansen P, Nielsen TH (1990) Treatment of migraine with drugs related to 5-hydroxytryptamine. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine, prospective therapeutic applications. Kluwer, Dordrecht, pp 433–441

    Google Scholar 

  68. Tfelt-Hansen P, Standnes B, Kangasniemi P, Hakkarainen H, Olesen J (1984) Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 69:1–8

    Google Scholar 

  69. Tfelt-Hansen P, Brand J, Dano P, Doenicke A, Findley LJ, Iversen HK, Melchart D, Sahlender HM (1989) Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia 9 (suppl 9):73–77

    Google Scholar 

  70. Weerasuriya K, Patel L, Turner P (1982) Beta-adrenoceptor blockade and migraine. Cephalalgia 2:33–45

    Google Scholar 

  71. Wilkinson M (1980) The treatment of migraine. J Drug Res 5 (suppl):44–52

    Google Scholar 

  72. Zaimis E, Hanington E (1969) A possible pharmacological approach to migraine. Lancet II:298–300

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Medicine, Erasmus University, PO Box 1738, 3000 DR, Rotterdam, The Netherlands

    P. R. Saxena & M. O. Den Boer

Authors
  1. P. R. Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. O. Den Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saxena, P.R., Den Boer, M.O. Pharmacology of antimigraine drugs. J Neurol 238 (Suppl 1), S28–S35 (1991). https://doi.org/10.1007/BF01642903

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01642903

Key words

Search

Navigation